188P - Molecular profiling of non-small cell lung cancer with cytologic specimens in the absence of histologic specimens

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Translational Research
Non-Small Cell Lung Cancer
Basic Principles in the Management and Treatment (of cancer)
Presenter David Heigener
Citation Annals of Oncology (2014) 25 (suppl_4): iv58-iv84. 10.1093/annonc/mdu326
Authors D. Heigener1, M. Falk2, A. Kanappilly3, M. Tiemann4, M. Reck1, L. Welker3
  • 1Thoracic Oncology, LungenClinic Grosshansdorf, 22927 - Grosshansdorf/DE
  • 2Molecular Biology, Institute for Hemato-Pathology, 22547 - Hamburg/DE
  • 3Cytology, LungenClinic Grosshansdorf, 22927 - Grosshansdorf/DE
  • 4Molecular Pathology, Hematopathology Hamburg, 22547 - Hamburg/DE



Non-Small Cell Lung Cancer (NSCLC) harbours different mutations and gene-rearrangements which should be tested because of predictive or prognostic impact. Although histologic specimens are considered as “Gold Standard” -especially for performing multiple tests-, cytologic specimens are often the only available in NSCLC


We retrospectively analysed the molecular results (KRAS, EGFR, EML4- ALK, p53) of cytologies of patients diagnosed from January through December 2013 in the LungenClinic Grosshansdorf. Specimens were eligible for molecular testing when they consisted of approximately 100 tumor cells or more and a tumor content of approximately 30% within the specimen. KRAS was analysed by direct sequencing, EGFR was detected with the cobas-Method, p53 with Next Generation Sequencing (NGS) and EML4-ALK with Flourescence in-situ hybridisation (FISH). Patients with additional histologic specimens were excluded from this analysis.


113 patients had cytology only without additional histologic material. These consisted of 1 imprint biopsy, 88 fine needle aspirations, 2 brush biopsies and 22 pleural effusions. The material from all 113 patients consisted of 101 adenocarcinomas, 1 squamous cell carcinoma and 11 NSCLC not otherwise specified. EGFR-testing was performed in all 113 patients with 12 harbouring an activating mutation (10.6%). KRAS-testing was performed in 107 patients with 30 harbouring a mutation (28%). In 5 specimens, material was insufficient, 1 was not tested. In 39 cases FISH for detection of an ALK-Rearrangement was done, 4 specimens were insufficient (10.2%) and one was tested positive. Of all, 91 specimens were eligible for p53-Testing with NGS with 34 tested positive (37%).


With adequate cytologic material, molecular analyses –even multiple tests- are realizable.


All authors have declared no conflicts of interest.